glp-1 and ckd Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations | Diabetes Therapy New Hope for Kidney Disease:

Behavioral habits formed on-drug may partially persist after discontinuation, but the population making active dietary choices based on pharmaceutical appetite suppression is always in flux

While important to know about, this warning is based on animal studies and the link has not been found in humans

Compliance with both the Health Insurance Portability and Accountability Act and General Data Protection Regulation is maintained by the TriNetX platform 42,43

GLP-1 Medications and Dehydration: What You Need to Know One indirect kidney concern with GLP-1 therapy involves adequate hydration, since these medications reduce appetite and can slow gastric emptying, potentially decreasing fluid intake